Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis
This article was originally published in Pharmaceutical Approvals Monthly
Positive Phase II results for GlobeImmune's immune-boosting hepatitis C vaccine GI-5005 were underscored at the European Association for the Study of the Liver meeting in Vienna April 17 by results from a newly available biomarker test that shows the therapy is most effective at clearing the virus from patients whose genetic status predicts little chance for complete recovery
You may also be interested in...
GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011